• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.

作者信息

Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci P M, Violi F

机构信息

Institute of Clinical Medicine I, University of Rome, La Sapienza, Italy.

出版信息

Hepatology. 1996 Jun;23(6):1377-83. doi: 10.1002/hep.510230613.

DOI:10.1002/hep.510230613
PMID:8675154
Abstract

The aim of this study was to evaluate whether there is endothelial dysfunction in patients with cirrhosis and to detect the mechanism that may account for it. We measured plasma levels of von Willebrand factor (vWF), a marker of endothelial perturbation, and endotoxin, which releases vWF from endothelial cells in vitro, in 32 patients (18 men, 14 women, aged 39-70 years) with cirrhosis classified as mild (class A, n = 10), moderate (class B, n = 16), or severe (class C, n = 6) according to Child-Pugh's classification. vWF antigen (P < .0001) and endotoxemia (P < .0001) progressively increased from A to class C; but the increase of vWF antigen was not strictly related to liver failure, as shown by the lack of correlation between vWF and several indexes of liver protein synthesis. Analysis of the vWF subunit showed no sign of proteolytic fragmentation of the molecule. Multimeric analysis indicated intact vWF multimeric structure. In all patients, there was a strong correlation between vWF antigen and endotoxemia (rho = .92; P = .0001). In 20 selected patients, vWF antigen and endotoxemia were measured before and after 7 days of standard therapy (n = 10) or standard therapy plus nonabsorbable antibiotics. There was a significant decrease of vWF antigen (P < .02) concomitantly with the decrease of endotoxemia (P < .006) in patients taking nonabsorbable antibiotics. Human umbilical vein endothelial cells incubated in vitro with 125 to 500 pg/mL endotoxin released vWF antigen into the medium dose dependently. These results demonstrate that there is endothelial perturbation in cirrhosis and that endotoxemia may play a key role in its occurrence.

摘要

相似文献

1
High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.
Hepatology. 1996 Jun;23(6):1377-83. doi: 10.1002/hep.510230613.
2
Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: a potential role for endothelial procoagulant activation.肝硬化中低度内毒素血症引起的全身凝血激活:内皮促凝激活的潜在作用。
Ital J Gastroenterol Hepatol. 1997 Oct;29(5):434-40.
3
Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: the Frederiksberg heart failure study.收缩期心力衰竭稳定门诊患者的血浆血管性血友病因子和可溶性E选择素水平:腓特烈斯贝格心力衰竭研究
Int J Cardiol. 2007 Jun 25;119(1):80-2. doi: 10.1016/j.ijcard.2006.07.085. Epub 2006 Oct 5.
4
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.血管性血友病因子水平可预测肝硬化合并门静脉高压患者的临床结局。
Gut. 2011 Aug;60(8):1133-8. doi: 10.1136/gut.2010.235689. Epub 2011 Mar 22.
5
Homocysteine and endothelial markers are increased in patients with chronic liver diseases.同型半胱氨酸和内皮细胞标志物在慢性肝病患者中升高。
Eur J Intern Med. 2009 Sep;20(5):482-6. doi: 10.1016/j.ejim.2009.03.002. Epub 2009 Apr 2.
6
Endothelial cell activation in cutaneous vasculitis.皮肤血管炎中的内皮细胞活化
Clin Exp Dermatol. 1996 Jan;21(1):28-32.
7
Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.获得性血管性血友病综合征患者血浆中血管性血友病因子及其前肽的定量分析
Thromb Haemost. 1998 Sep;80(3):495-8.
8
High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men.高剂量地塞米松会增加健康男性循环中的P-选择素和血管性血友病因子水平。
Thromb Haemost. 2005 Oct;94(4):797-801. doi: 10.1160/TH04-10-0652.
9
Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels.血流介导的血管舒张功能受损作为慢性心房颤动内皮功能障碍的证据:与血浆血管性血友病因子和可溶性E选择素水平的关系。
Thromb Res. 2008;122(1):85-90. doi: 10.1016/j.thromres.2007.09.008. Epub 2007 Nov 8.
10
Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.增殖性视网膜病变中的血浆血管内皮生长因子及可溶性血管内皮生长因子受体FLT-1:与内皮功能障碍及激光治疗的关系
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2115-9.

引用本文的文献

1
Nomogram model for identifying portal vein thrombosis in patients with decompensated cirrhosis.用于识别失代偿期肝硬化患者门静脉血栓形成的列线图模型
Eur J Gastroenterol Hepatol. 2025 Aug 1;37(8):935-942. doi: 10.1097/MEG.0000000000002968. Epub 2025 Mar 26.
2
Non-invasive assessment of portal hypertension: Liver stiffness and beyond.门静脉高压的非侵入性评估:肝脏硬度及其他方面。
JHEP Rep. 2024 Dec 11;7(3):101300. doi: 10.1016/j.jhepr.2024.101300. eCollection 2025 Mar.
3
Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma.
血管性血友病因子抗原可改善可切除肝细胞癌患者的风险分层。
Ann Surg Oncol. 2024 Oct;31(10):6526-6536. doi: 10.1245/s10434-024-15618-w. Epub 2024 Jun 19.
4
Assaying ADAMTS13 Activity as a Potential Prognostic Biomarker for Sinusoidal Obstruction Syndrome in Mice.检测 ADAMTS13 活性作为小鼠窦状隙阻塞综合征的潜在预后生物标志物。
Int J Mol Sci. 2023 Nov 15;24(22):16328. doi: 10.3390/ijms242216328.
5
Von Willebrand Factor as a Biomarker for Liver Disease - An Update.血管性血友病因子作为肝脏疾病的生物标志物——最新进展
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1047-1060. doi: 10.1016/j.jceh.2023.05.016. Epub 2023 Jun 2.
6
A model based on adipose and muscle-related indicators evaluated by CT images for predicting microvascular invasion in HCC patients.一种基于CT图像评估的脂肪和肌肉相关指标的模型,用于预测肝癌患者的微血管侵犯。
Biomark Res. 2023 Oct 4;11(1):87. doi: 10.1186/s40364-023-00527-z.
7
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome.晚期慢性肝脏疾病患者血管性血友病因子的处理及其与门静脉高压和临床结果的关系。
Hepatol Int. 2023 Dec;17(6):1532-1544. doi: 10.1007/s12072-023-10577-y. Epub 2023 Aug 21.
8
Viscoelastometry to Manage Bleeding in Liver Disease.运用粘弹性测定法处理肝病出血问题。
Cureus. 2023 Jul 5;15(7):e41401. doi: 10.7759/cureus.41401. eCollection 2023 Jul.
9
Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.改善门静脉高压的管理:非病因治疗在肝硬化中的潜在益处。
J Clin Med. 2023 Jan 25;12(3):934. doi: 10.3390/jcm12030934.
10
Low ADAMTS-13/VWF ratio and altered gut-liver axis predict complications of advanced chronic liver disease: a pilot study.低ADAMTS-13/血管性血友病因子(VWF)比值及肠道-肝脏轴改变可预测晚期慢性肝病并发症:一项初步研究
Gastroenterol Rep (Oxf). 2022 Nov 7;10:goac065. doi: 10.1093/gastro/goac065. eCollection 2022.